Differential effects of inhibition of interleukin 1 and 6 on myocardial, coronary and vascular function

Ikonomidis, Ignatios; Pavlidis, George; Katsimbri, Pelagia; Andreadou, Ioanna; Triantafyllidi, Helen; Tsoumani, Maria; Varoudi, Maria; Vlastos, Dimitrios; Makavos, George; Kostelli, G; Benas, D; Lekakis, John; Parissis, John; Boumpas, Dimitrios; Alexopoulos, Dimitrios; Iliodromitis, Efstathios K.

doi:10.1007/s00392-019-01443-9

Cited by 49 publications

(47 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Anti-inflammatory treatment may exert beneficial effect on endothelial glycocalyx and thus may offer protection from evolution to alveoli exudation ( 77 ). Moreover, anti-inflammatory treatment with tocilizumab but also anakinra—an IL 1 receptor antagonist—exhibit beneficial effects on vascular function and myocardial function ( 78 ), as has been shown in patients with rheumatoid arthritis.…”

Section: Echocardiography For Monitoring Treatment Effect On Myocardimentioning

confidence: 99%

“…Agents with inherent antioxidant properties such as N-acetylcysteine (NAC) and vitamin C may also be shown to be effective. The beneficial anti-inflammatory effect of monoclonal antibody treatment on myocardial function in COVID-19 infected patients may by easily monitored by an improvement in global longitudinal strain (GLS) toward normal values ( 81 ), as has been previously shown in patients with rheumatoid arthritis and uncontrolled inflammation ( 78 , 79 ). The lowest expected normal values for GLS are −16.7% in men and −17.8% in women, according to a recently proposed consensus document, and these are similar to the values reported after remission of the acute inflammatory exacerbations by biological agents in patients with rheumatoid arthritis ( 78 , 79 ).…”

Section: Echocardiography For Monitoring Treatment Effect On Myocardimentioning

confidence: 99%

See 1 more Smart Citation

The Dual Role of Echocardiography in the Diagnosis of Acute Cardiac Complications and Treatment Monitoring for Coronavirus Disease 2019 (COVID-19)

Vrettou

Parissis

Ikonomidis

2020

Front. Cardiovasc. Med.

Self Cite

View full text Add to dashboard Cite

The Coronavirus Disease 2019 (COVID-19) pandemic, being caused by an easily and rapidly spreading novel betacoronavirus, has created a state of emergency for people, the scientific community, healthcare systems and states, while the global financial consequences are still unfolding. Cardiovascular complications have been reported for COVID-19-infected patients and are associated with a worse prognosis. ECG and biomarkers may raise suspicion of cardiac involvement. However, transthoracic echocardiography is a fast and reliable bedside method to establish the diagnosis of cardiac complications, including acute coronary syndromes, pericarditis, myocarditis, and pulmonary embolism. Early detection of cardiac dysfunction by speckle tracking echocardiography during off-line analysis may be used to identify a high-risk population for development of heart failure in the acute setting. Precautionary measures are mandatory for operators and equipment to avoid viral dispersion. No specific treatment is yet available for severe acute respiratory syndrome coronavirus 2 (SARS-CoV 2), and a variety of antiviral, immune-modifying, and antioxidant agents are therefore under intense investigation. Echocardiography, including assessment of myocardial deformation, may provide a useful tool to monitor the effects of the various treatment regimens on cardiac function both acutely and in the midterm.

show abstract

Section: Echocardiography For Monitoring Treatment Effect On Myocardimentioning

confidence: 99%

Section: Echocardiography For Monitoring Treatment Effect On Myocardimentioning

confidence: 99%

The Dual Role of Echocardiography in the Diagnosis of Acute Cardiac Complications and Treatment Monitoring for Coronavirus Disease 2019 (COVID-19)

Vrettou

Parissis

Ikonomidis

2020

Front. Cardiovasc. Med.

Self Cite

View full text Add to dashboard Cite

show abstract

“…У пациентов с острой декомпенсацией ХСН отмечено улучшение среднего пика потребления кислорода и ФВЛЖ, при этом общая смертность и частота повторных госпитализаций не различались [62]. У больных РА анакинра ассоциируется с более выраженным улучшением глобальной продольной деформации и коронарного резерва по сравнению с тоцилизумабом и преднизолоном (18,7%, 9,7% и 6%; p<0,001 и 29%, 13% и 1%; p<0,001, соответственно) [63]. Описан случай значительного улучшения клинического состояния, толерантности к физической нагрузке и среднего пика кислорода у пациентки с РА, ожирением, АГ, сахарным диабетом и СНсФВ III-IV ФК по NYHA после замены терапии этанерцептом на анакинру [64].…”

Section: ингибирование ил-1βunclassified

“…Возможно, блокада ИЛ-6 приводит к уменьшению ММЛЖ и, как следствие, перегрузке ЛЖ, снижению уровня NTproBNP. У больных РА тоцилизумаб улучшал параметры деформации миокарда ЛЖ, эндотелиальную функцию, эластические свойства артериальной стенки, снижал оксидативный стресс и уровень маркеров воспаления [63]. В субанализе исследования TOWARD показано сопоставимое снижение уровня NT-proBNP на фоне комбинированной терапии с-БПВП с тоцилизумабом и с-БПВП без такового у больных РА [72].…”

Section: ингибирование ил-6unclassified

Chronic Heart Failure in Rheumatoid Arthritis Patients (Part III): Effects of Antirheumatic Drugs

Новикова¹,

Udachkina²,

Kirillova³

et al. 2020

Racionalʹnaâ farmakoterapiâ v kardiologii

View full text Add to dashboard Cite

Chronic autoimmune inflammation is one of the leading risk factors for the development of chronic heart failure (CHF) in rheumatoid arthritis (RA). The purpose of the review is to analyze the results of investigations on the effects of conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs), biological disease-modifying anti-rheumatic drugs (bDMARDs), and targeted csDMARDs on cardiac function and the risk of developing CHF in patients with RA. Methotrexate may reduce the CHF risk and have a positive effect on the course of this condition in patients with RA. Despite the data on the presence of leflunomide effects that impede myocardial remodeling, there is no evidence of the role of the drug in the prevention of CHF in RA patients. Hydroxychloroquine may contribute to the prevention of CHF, but the risk of developing severe cardiotoxicity should be considered when taking the drug for a long time. Most studies have not revealed the negative effect of tumor necrosis factor inhibitors on the prevalence and incidence of new cases of CHF in RA patients, and an improvement in the structure and function of the heart during therapy has been shown. Inhibitors of interleukin (IL) -1, inhibitors of IL-6, inhibitors of T-cell co-stimulation, anti-B-cell therapy, targeted csDMARDs do not increase the risk of CHF and may have cardioprotective effects, including slowing the progression of left ventricle myocardial dysfunction. Due to the high risk of CHF and CHF-associated mortality in RA patients, early diagnosis of cardiac dysfunction, development of a prevention and treatment strategies are needed, including high-quality prospective studies to assess the effect of anti-rheumatic therapy on myocardial function, risk of developing and decompensation of CHF in RA patients. It is possible that some drugs may possess protective effects on cardiomyocytes so they could become the first-line drugs in patients with CHF or the risk of its development.

show abstract

“…The use of IL-6 inhibition alone in TA has also been demonstrated to be effective, but the evidence is still limited [ 14 ]. Furthermore, IL-6 blockade in patients with rheumatic diseases is associated with an improvement of vascular function [ 15 ]. Considering the severe manifestations of AA amyloidosis in our patient, the first goal of therapy was the reduction of proteinuria and the prevention of further renal damage.…”

mentioning

confidence: 99%

Renal AA amyloidosis leading to early diagnosis and treatment of takayasu arteritis: a case report and review of the literature

2020

View full text Add to dashboard Cite

Differential effects of inhibition of interleukin 1 and 6 on myocardial, coronary and vascular function

Cited by 49 publications

References 52 publications

The Dual Role of Echocardiography in the Diagnosis of Acute Cardiac Complications and Treatment Monitoring for Coronavirus Disease 2019 (COVID-19)

The Dual Role of Echocardiography in the Diagnosis of Acute Cardiac Complications and Treatment Monitoring for Coronavirus Disease 2019 (COVID-19)

Chronic Heart Failure in Rheumatoid Arthritis Patients (Part III): Effects of Antirheumatic Drugs

Renal AA amyloidosis leading to early diagnosis and treatment of takayasu arteritis: a case report and review of the literature

Contact Info

Product

Resources

About